Scienza e Tecnologia
XNK Therapeutics to present at Redeye's Regenerative Medicine/Cell Therapy event on February 23
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and lead investigational candidate drug was developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Company's objective is for its investigational candidate drug and proprietary platform technology to constitute key components in the cancer treatments of tomorrow. XNK Therapeutics is headquartered in Stockholm, Sweden . For more info, please visit www.xnktherapeutics.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/xnk-therapeutics-ab/r/xnk-therapeutics-to-present-at-redeye-s-regenerative-medicine-cell-therapy-event-on-february-23,c3511424
The following files are available for download: